Bacteriological profile of intra-abdominal infections in a tertiary care hospital

Sukanya Sudhaharan, Padmaja Kanne*, Lakshmi Vemu, Padmasri Chavali, Shanker Rao Desmukha, Bheerappa Nagari

Nizam's Institute of Medical Sciences Panjagutta, Hyderabad, Telangana, India

Received: January 2018, Accepted: June 2018

ABSTRACT

Background and Objectives: Intra-abdominal infections (IAIs) include a wide spectrum of pathological conditions, ranging from uncomplicated appendicitis to fecal peritonitis. The resulting infections should be diagnosed early and treated based on the organism isolated and its susceptibility. In this study the bacteriological profile and antimicrobial resistance pattern of intra-abdominal infections was analyzed.

Materials and Methods: A retrospective analysis of samples received from 119 cases of intra-abdominal infections in our Institute from January 2015 to December 2017 was analyzed. Patients with primary peritonitis from cirrhosis or ascites were not included in the study. The specimens were primarily processed, as per standard methods. Identification and antimicrobial susceptibility testing was done by the Vitek-2 system. Anaerobic culture was performed on 5% sheep blood agar plates and incubated in GEN bag anaerobic pouches.

Results: In our study perforative peritonitis 43/119 (36.1%) was predominant IAI followed by acute pancreatitis 14/119 (11.7%) and pancreatic necrosis 12/119 (10%). Microbial growth was observed in 66.3% (79/119) of the cases and combined infections were observed in 14/119 (11.7%) of the cases. Escherichia coli was the predominant organism isolated in 58/119 (40.8%), out of which 41/58 (70.6%) were ESBL producers and 16 /58 (27.5%) were multi drug resistant isolates. Klebsiella pneumoniae was isolated from 11/119 (9.2%) cases out of which 8/11 (72.7%) were ESBL and 3/11 (27.2%) were multidrug resistant isolates. Post-operative complications was observed in 12/119 (10%) patients with mortality in 15/119 (12.6%) patients.

Conclusion: Early diagnosis and appropriate management of the infections will help to prevent the morbidity and mortality associated with these infections.

Keywords: Pancreatic necrosis, Perforation, Cholecystitis, Appendicitis

INTRODUCTION

Intra-abdominal infections (IAIs) include a wide spectrum of pathological conditions, ranging from uncomplicated appendicitis to fecal peritonitis (1). The resulting infection is typically polymicrobial.
INTRA-ABDOMINAL INFECTIONS

and comprised of both aerobic and anaerobic microbes, which need systemic antimicrobial therapy (2). Antibiotic therapy has to be modified based on culture and susceptibility testing. Surgery along with appropriate antibiotics will help to reduce the morbidity and mortality associated with intra-abdominal infections.

Aim & objectives of this study were: 1) To study the bacteriological profile and antimicrobial resistance pattern of the organisms isolated from IAI and 2) To study the type of IAI, organ involved and mortality associated with IAI.

MATERIALS AND METHODS

A retrospective analysis of samples received from 119 cases of intra-abdominal infections undergoing surgery or interventional drainage in our institute from January 2015 to December 2017 was analyzed. Patients with primary peritonitis from cirrhosis or ascites were not included in the study.

The specimens such as peritoneal fluids, pus, bile, ascitic fluid received to the microbiology department were primarily processed, as per standard methods, on 5% sheep blood agar (aerobic and anaerobic) and Chromogenic agar (CPS ID, bioMerieux, Marc Elitoile, France) and also inoculated into Bact/Alert SN bottles. Identification and antimicrobial susceptibility testing was done by the Vitek-2 system (bioMerieux, Marc Elitoile, France). Anaerobic culture was performed on 5% sheep blood agar plates and incubated in GEN bag anaerobic pouches (bioMerieux, Marc El Etoile- France).

RESULTS

In our study perforative peritonitis, 43/119 (36.1%), was predominant infection followed by acute pancreatitis 14/119 (11.7%) and pancreatic necrosis 12/119 (10%). Other infections include cholecystitis, cholelithiasis, cholecdocholithiasis (Table 1). Perforations of abdominal organs include small bowel, appendix, gall bladder, stomach, duodenum and colon. (Fig. 1). Small bowel is the common organ perforated in 28/43 (65.1%) of the cases.

As per organ type involved pancreas was the predominant organ involved in 40/119 (33.6%) cases (Table 2).

Microbial growth was observed in 66.3% (79/119) of the patients and among them 14/119 (11.7%) were combined infections (Table 1). E. coli was the predominant organism isolated in 58/119 (40.8%) of IAI’s, of which 41/58 (70.6%) were ESBL producers and 16/58 (27.5%) were multi drug resistant isolates. K. pneumoniae was isolated from 11/119 (9.2%) cases of which 8/11 (72.7%) were ESBL and 3/11 (27.2%) were multidrug resistant isolates. Other organisms isolated include K. pneumonia, Proteus mirabilis, and Pseudomonas aeruginosa (Table 2).

Majority of the E. coli was isolated in cases with small bowel perforation 18/58 (31%) followed by cholecystolithiasis 8/58 (13.7%) (Table 2). Other Gram negative and Gram positive organisms isolated in different IAI’s are shown in Tables 2–4. The antibiotic susceptibility pattern of the organisms is listed in Tables 5 and 6.

DISCUSSION

Intra-abdominal infection varies widely, ranging from peritonitis to intrahepatic infection to diverticulitis, appendicitis, and intra-abdominal abscess. IAI’s are common surgical emergencies and they are responsible for non-trauma deaths worldwide (3).

The pathogenesis of intra abdominal infections is determined by bacterial factors which influence the transition from contamination to infection. Bacterial
Table 1. Total No of cases (n=119)

| Infection                      | Sterile | Monomicrobial infections | Polymicrobial infections | Total |
|--------------------------------|---------|--------------------------|--------------------------|-------|
| Acute pancreatitis             | 6       | 8                        | 0                        | 14    |
| Chronic pancreatitis           | 2       | 2                        | 1                        | 5     |
| Pancreatic necrosis            | 3       | 5                        | 4                        | 12    |
| Pancreatic pseudocyst          | 4       | 5                        | 0                        | 9     |
| Appendicular abscess           | 2       | 2                        | 0                        | 4     |
| Acute cholecystitis            | 2       | 0                        | 0                        | 2     |
| Cholangitis                    | 1       | 7                        | 1                        | 9     |
| Choledochal cyst               | 4       | 1                        | 1                        | 6     |
| Choledocholitihiasis           | 1       | 9                        | 2                        | 12    |
| Cholelithiasis                 | 2       | 1                        | 0                        | 3     |
| Perforations (n=43)            |         |                          |                          |       |
| Appendix                       | 2       | 0                        | 0                        | 2     |
| Gall bladder                   | 2       | 5                        | 0                        | 7     |
| Colon                          | 1       | 1                        | 0                        | 2     |
| Stomach                        | 1       | 0                        | 0                        | 1     |
| Duodenum                       | 1       | 2                        | 0                        | 3     |
| Small bowel                    | 6       | 17                       | 5                        | 28    |
| Total IAI’S                    | 40      | 65                       | 14                       | 119   |

Table 2. Gram negative bacilli isolated

| Infection                      | Escherichia coli | Klebsiella pneumoniae | Proteus mirabilis | Pseudomonas aeruginosa |
|--------------------------------|------------------|-----------------------|-------------------|-----------------------|
| **Pancreas**                   |                  |                       |                   |                       |
| Acute pancreatitis             | 5                | 0                     | 1                 | 0                     |
| Chronic pancreatitis           | 2                | 0                     | 1                 | 0                     |
| Pancreatic necrosis            | 5                | 2                     | 2                 | 0                     |
| Pancreatic pseudocyst          | 2                | 0                     | 0                 | 0                     |
| Total                          | 14               | 2                     | 4                 | -                     |
| **Appendix**                   |                  |                       |                   |                       |
| Appendicular abscess           | 2                | 0                     | 0                 | 0                     |
| **Gall bladder**               |                  |                       |                   |                       |
| Cholangitis                    | 7                | 1                     | 0                 | 1                     |
| Choledochal cyst               | 2                | 0                     | 0                 | 0                     |
| Choledocholitihiasis           | 8                | 2                     | 0                 | 0                     |
| Cholelithiasis                 | 1                | 0                     | 0                 | 0                     |
| Total                          | 18               | 3                     | -                 | 1                     |
| **Perforation**                |                  |                       |                   |                       |
| Gall bladder perforation       | 4                | 1                     | 0                 | 0                     |
| Duodenal perforation           | 2                | 0                     | 0                 | 0                     |
| Colon perforation              | 0                | 1                     | 0                 | 0                     |
| Small bowel perforation        | 18               | 5                     | 0                 | 0                     |
| Total                          | 24               | 7                     | -                 | -                     |
| TOTAL                          | 58               | 12                    | 4                 | 1                     |
Table 3. Other Gram negative bacilli isolated

| Organisms                     | No of cases | Infection                          |
|-------------------------------|-------------|------------------------------------|
| Enterobacter cloacae         | 2           | Pancreatic Pseudocyst              |
| Stenotrophomonas             | 3           | Chronic pancreatitis               |
| S. maltophilia               | 1           | Acute pancreatitis                 |
| Morganella morganii          | 2           | Pancreatic necrosis                |
| Aeromonas hydrophila         | 1           | Pancreatic necrosis                |
| Burkholderia cepacia         | 1           | Choleodocholithiasis               |
| Citrobacter freundii         | 1           | Pancreatic necrosis                |
| Bacteroides                  | 2           | Acute pancreatitis                 |

Table 4. No of Gram positive cocci isolated

| Infection                  | MRSA | MSSA | Enterococcus |
|----------------------------|------|------|--------------|
| Chronic pancreatitis       | 1    | 0    | 0            |
| Pancreatic pseudocyst      | 0    | 1    | 0            |
| Choleodocholithiasis       | 0    | 0    | 1            |
| Small bowel perforation    | 0    | 0    | 3            |
| Total                      | 1    | 1    | 4            |

Table 5. Antibiotic susceptibility pattern of Gram negative isolates

| Organisms                          | % Susceptibility to specified antibiotics |
|------------------------------------|------------------------------------------|
|                                    | Amikacin | Gentamicin | Ciprofloxacin | Levofloxacin | Cotrimoxazole | Cefazidine | Ceftazime | Imipenem | Meropenem | Pip/Taz | Sulb/cefape | Colistin | Tigecycline |
| Escherichia coli                   | 58      | 48.8      | 11.9         | 11.9         | 10.8        | 1.7       | 1.7       | 70.6     | 70.6      | 47      | 42.3        | 100      | 100         |
| Klebsiella pneumoniae             | 12      | 45.7      | 45.7         | 12.9         | 12.9        | 11.4      | 0         | 0        | 72.7      | 72.7    | 14.3        | 21.4     | 81.4        |
| Proteus mirabilis                 | 4       | 75        | 75           | 50           | 50          | 75        | 0         | 0        | 50        | 100     | 100         | 100      | 100         |
| Pseudomonas aeruginosa            | 1       | 100       | 0            | 0            | 0           | 0         | 0         | 0        | 100       | 100     | 100         | 100      | 100         |
| Enterobacter cloacae              | 2       | 100       | 100          | 0            | 0           | 100       | 100       | 100      | 100       | 100     | 100         | 100      | 100         |
| Stenotrophomonas S. maltophilia   | 3       | IR        | IR           | IR           | IR          | 100       | 100       | 100      | 100       | 100     | 100         | NT       | NT          |
| Morganella morganii               | 1       | 100       | 100          | 0            | 0           | 100       | 100       | 100      | 100       | 100     | 100         | 100      | 100         |
| Aeromonas hydrophila              | 2       | 100       | 100          | 100          | 50          | 100       | 100       | 50       | 100       | 100     | 50          | 100      | 100         |
| Burkholderia cepacia              | 1       | 100       | 100          | 100          | 100         | 100       | 100       | 100      | 100       | 100     | 100         | NT       | NT          |

IR Intrinsically resistant
NT Not tested

Activation leads to transmigration of granulocytes resulting in increased permeability, edema and protein rich peritoneal exudates (4).

Perforative peritonitis was seen in 36.1% of our cases. Perforation is one of the serious infections which require immediate surgery and both aerobic and anaerobic flora are isolated from peritoneal fluid (3). In a study from India about the spectrum of peritonitis, they found that gastroduodenal perforation is most common accounting for 54.2% of the cases (5) in contrast to our study. In a study from Serbia, they found that small bowel perforations accounted for 23% of the cases (6) whereas in our study it is the commonest of perforations accounting for 65.1%. Our patients were treated by surgery with closure of perforation & resection and anastomosis.

In a study by CIOWA (7) most of the cases of IAI are due to appendicitis (33.3%) followed by cholecystitis (14.6%) and small bowel perforation (7.6%). The involvement of appendix was low in our study indicating less complicated course of the disease requiring referral to a tertiary care centre. Reshetnyak et al. found that in Western countries, gallstone disease in men was 7.9% and it was 16.6% in women (8) whereas Sun et al. found in Asia, it ranged 3-15% (9), as in our study stones in the gall bladder accounted for 15/119 (12.6%) of the cases followed by cholangitis in
Table 6. Antibiotic susceptibility pattern of Gram positive isolates

| Organisms                  | No. of Isolates | % Susceptibility to specified antibiotics |
|---------------------------|-----------------|------------------------------------------|
|                           |                 | Penicillin | Oxacillin | Gentamicin | Ciprofloxacin | Levofloxacin | Cotrimoxazole | Tetracycline | Chloramphenicol | Erythromycin | Linezolid | Vancomycin | Teicoplanin | Daptomycin | Teicoplanin | Daptomycin |
| MRSA                      | 1               | 0          | 0         | 0         | 0            | 0            | 0            | 0            | 0              | 0            | 0         | 0          | 0          | 0          | 0          | 0          | 0          | 0          |
| MSSA                      | 1               | 100        | 100       | 0         | 0            | 0            | 100          | 100          | 100            | 100          | 100       | 100        | 100        | 100        | 100        | 100        |
| Enterococcus faecium      | 4               | 0          | 0         | IR        | IR           | 0            | 50           | IR           | 0              | 100          | 100       | 100        | 100        | 100        | 100        | 100        |

IR Intrinsically resistant
NT Not tested

Fig. 2. Mortality

7.5% of the cases.

In our study pancreas was the predominant organ involved. Pancreatitis and pancreatic necrosis together contribute to 31/119 (26%) of cases and bacterial growth was observed in 20/31 (64.5%) of cases. Pancreatic necrosis if infected is an important risk factor and it should be treated by surgery (10). All our cases were treated with surgery and removal of necrosum followed by appropriate antibiotics therapy. In a study by Dionigi R et al. they found that enteric Gram negative bacilli are commonly isolated from acute pancreatitis (11). E. coli was isolated in 36.7% of our cases of pancreatic infection.

In a study by Goldstein et al. the most common organism isolated in cases of perforation was E. coli (51.72%) followed by Klebsiella (29.31%) (2). Similar to our study E. coli was predominant organism followed by Klebsiella. In the study of Goldstein et al. acute appendicitis was the most common condition requiring emergency surgery (2). In a study by Lahiri et al. from India, the commonest organism isolated was E. coli (67.78%) (12) as in our study.

The presence of gallstones within either the gallbladder or biliary tree is associated with the bacterial colonization of the bile. Similar to our study, E. coli was the most common organism isolated in a study conducted by Ballal et al. from India (13).

E. coli (62.7%), K. pneumoniae (16.7%), and P. aeruginosa (5.3%) were the most frequently isolated pathogens in IAI’s from India in a study conducted by Shree et al. (14). As per literature review (1, 2, 13, 14), E. coli was the most frequent pathogen associated with IAI which is similar to our study where E. coli was isolated from 40.8% of cases.

There is an increase of extended spectrum β-lactamase (ESBL) and multi-drug resistant (MDR) isolates worldwide in the study by Shree et al. (14). Among the intra-operative isolates, ESBL producing E. coli isolates comprised 13.7%, while ESBL-positive K. pneumoniae isolates represented 18.6% in the study done by CIOWA (7). There was a higher percentage of ESBL producers in E. coli (70.6%) and K. pneumoniae (72.5%) in our study also which is of increasing concern.

In the study by Goldstein et al, they described the emergence of multidrug-resistant (MDR) Gram-negative bacteria such as P. aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia from IAI’s (2). In a study from Greece, 8.8% of intra-abdominal infections is caused by S. maltophilia and is intrinsically resistant to multiple classes of antibiotics due to different mechanism of resistance.
The drug of choice for infection with this organism is trimethoprim/sulfamethoxazole (15). In our study, we isolated *P. aeruginosa* from one patient with cholangitis, *S. maltophilia* in 3 patients and one *burkholderia cepacia* from a case of pancreatic necrosis. These infections are mostly hospital acquired and are multidrug resistant and require strict infection prevention control measures (14).

*Bacteroides fragilis* accounts for only 0.5% of the normal colonic flora, hence is recognized as the single most important anaerobic pathogen (3). In study of Goldstein et al, *Bacteroides* accounted for 34.6% of the anaerobes isolated from IAI (16). Metronidazole is the choice of therapy for *Bacteroides* (17).

We isolated *Bacteroides* from 2 cases of pancreaticitis which was low compared to other studies which might have been due to the empirical therapy with metronidazole given to our patients.

*Enterococcus* is the commonest Gram positive bacteria isolated from IAI’s (7). In a study by Marcus et al. they isolated 5 cases of *Enterococcus* and one case of methicillin resistant *S. aureus* (MRSA) from IAI (18). In our study we isolated four cases of *E. faecium* and one case of MRSA. *Enterococcus* does not have a poor prognosis and empiric therapy is not recommended for these organism in community acquired infections (18), whereas it is more prevalent in hospital acquired infections requiring antibiotic therapy (7). In a study from France they found that IAI’s due to MRSA may be due to nasal colonization (19). The source of infection in our case could not be traced.

Our patients were empirically treated with piperacillin-tazobactum, amikacin and metronidazole. As per IDSA guidelines metronidazole is given as an intravenous infusion of 500 mg every 8-12 hr or 1500 mg every 24 h, intravenous piperacillin-tazobactam 3.375 g every 6 hr and amikacin 15-20 mg/kg every 24 h. The therapy can be discontinued if there is no evidence of infection (20). In patients with post-operative complications and in infections with drug resistant isolates antibiotics were changed based on drug susceptibility reports. Around 27% of *E. coli* and *K. pneumoniae* were MDR isolates and they were sensitive to colistin. All these patients were treated with intravenous colistin 3MU every 8th hourly.

Post-operative complications should be managed intensively with broad spectrum antibiotics for sepsis, leakage, additional surgeries and controlling the source of complication (4). In our study it was less accounting for 10% of the cases.

The rate of mortality was significantly higher in patients with higher degree of pancreatic necrosis from 5-40% as reported by Pal et al. (21). In our study mortality was higher (7/12, 58%) in pancreatic necrosis of all pancreatic involvement, probably due to the higher degree of necrosis in our patients.

The other important cause of mortality in intraabdominal infections is perforative peritonitis (22) and the mortality ranges from 6 and 27% as reported by Oheneh et al. (23) and in small bowel perforations which is common it accounts between 10 and 36.5% according to the report of Bapat et al. (24). Mortality due to perforations was 8/43 (19%) in our study.

As our institute is a tertiary care centre we had complicated cases like pancreatic necrosis and less severe case of acute appendicitis. Multi drug resistant organisms, mostly hospital acquired, were successfully treated as per susceptibility results. All multidrug resistant cases were advised to follow proper infection control measures. There was no significant difference in the organism isolated and organ of infection. Hence empirical treatment can be started based on hospital antibiogram which helps to prevent complications associated with hospital acquired IAI’s.

In conclusion, initial empirical antibiotic therapy should be modified based on the organism isolated and susceptibility results. In addition, patients with intra-abdominal infections should be administered the most potent antibiotics immediately rather than the most commonly used antibiotics. Early diagnosis and appropriate management of the infections will help to prevent the morbidity and mortality associated with these infections.

REFERENCES

1. Sartelli M. A focus on intra-abdominal infections. *World J Emerg Surg* 2010;5:9.
2. Goldstein EJ. Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents. *Clin Infect Dis* 2002;35:S106-111.
3. Sartelli M, Chichom-Mefire A, Labricciosa FM, Hardcastle T, Abu-Zidan FM, Adesunkanmi AK, et al. The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for man-
agement of intra-abdominal infections. World J Emerg Surg 2017; 12:29.
4. Farthmann EH, Schoffe U. Epidemiology and pathophysiology of intraabdominal infections (IAI). Infection 1998;26:329-334.
5. Chakma SM, Singh RL, Parmekar MV, Singh KH, Kapa B, Sharatchandra KH, et al. Spectrum of perforation peritonitis. J Clin Diagn Res 2013;7:2518-2520.
6. Doklestic SK, Bajec DD, Djukic RV, Bumbasirevic V, Detanac AD, Detanac SD, et al. Secondary peritonitis - evaluation of 204 cases and literature review. J Med Life 2014;7:132-138.
7. Sartelli M, Catena F, Ansaloni L, Coccolini F, Corbella D, Moore EE, et al. Complicated intra-abdominal infections worldwide: the definitive data of the CIAOW Study. World J Emerg Surg 2014; 9:37.
8. Reshetnyak VI. Concept of the pathogenesis and treatment of cholelithiasis. World J Hepatol 2012;4:18-34.
9. Sun H, Tang H, Jiang S, Zeng L, Chen EQ, Zhou TY, et al. Gender and metabolic differences of gallstone diseases. World J Gastroenterol 2009; 15:1886-1891.
10. Büchler MW, Gloor B, Müller CA, Friess H, Seiler CA, Uhl W. Acute necrotizing pancreatitis: treatment strategy according to the status of infection. Ann Surg 2000; 232:619-626.
11. Dionigi R, Rovera F, Dionigi G, Diurni M, Cuffari S. Infected pancreatic necrosis. Surg Infect (Larchmt) 2006;7:S49-52.
12. Lahiri S. Bacterial pattern of appendix in acute and chronic appendicitis with its clinical correlation. J Evolution Med Dent Sci 2016; 5:418-421.
13. Ballal M, Jyothi KN, Antony B, Arun C, Prabhu T, Shivananda PG. Bacteriological spectrum of cholecystitis and its antibiogram. Indian J Med Microbiol 2001; 19:212-214.
14. Shree N, Arora BS, Mohil RS, Kasana D, Biswal I. Bacterial profile and patterns of antimicrobial drug resistance in intra-abdominal infections: current experience in a teaching hospital. Indian J Pathol Microbiol 2013;56:388-392.
15. Samonis G, Karageorgopoulos DE, Maraki S, Levis P, Dimopoulou D, Spernvasilis NA, et al. Stenotrophomonas maltophilia infections in a general hospital: patient characteristics, antimicrobial susceptibility, and treatment outcome. PLoS One 2012;7(5):e37375.
16. Goldstein EJ, Citron DM. Annual incidence, epidemiology, and comparative in vitro susceptibilities to cefoxitin, cefotetan, cefmetazole, and ceftizoxime of recent community-acquired isolates of the Bacteroides fragilis group. J Clin Microbiol 1988;26:2361-2366.
17. Lofmark S, Edlund C, Nord CE. Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin Infect Dis 2010;50:S16-23.
18. Marcus G, Levy S, Saltab G, Mengesha B, Tzuman O, Shur S, et al. Intra-abdominal infections: the role of Anaerobes, Enterococci, Fungi, and multidrug-resistant organisms. Open Forum Infect Dis 2016; 3(4):ofw232.
19. Fierobe L, Decré D, Müller C, Lucet JC, Marmuse JP, Mantz J, et al. Meticillin-resistant Staphylococcus aureus as a causative agent of postoperative intra-abdominal infection: relation to nasal colonization. Clin Infect Dis 1999;29:1231-1238.
20. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the surgical infection society and the infectious diseases society of America. Clin Infect Dis 2010;50:133-164.
21. Pal KM, Kasi PM, Tayyeb M, Mosharraf SM, Fatmi Z. Correlates of morbidity and mortality in severe necrotizing pancreatitis. ISRN Surg 2012;2012:215193.
22. Goldstein EJ, Snyder DJ. Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy. J Antimicrob Chemother 2004; 53 Suppl 2:i29-36.
23. Oheneh YM. Postoperative complications after surgery for typhoid ileal perforation in adults in Kumasi. West Afr J Med 2007;26:32-36.
24. Bapat RD, Supe AN, Sathe M. Management of small bowel perforation with intra- and post-operative lavages with povidone iodine. (A prospective study). J Postgrad Med 1983; 29:29-33.